<DOC>
	<DOCNO>NCT01301833</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy MP-513 ( Teneligliptin ) monotherapy combination oral antihyperglycaemic agent patient type 2 Diabetes 52 week administration .</brief_summary>
	<brief_title>Long-term Safety Study MP-513 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<criteria>Patients receive stable dose regimen oral antihyperglycaemic agent ( biguanide agent , Î±glucosidase inhibitor , rapid insulin secretagogue ) diabetes 12 week administration investigational drug Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug Patients whose HbA1c 6.5 % 10.0 % Patients administer diabetes therapeutic drug prohibit concomitant use within 12 week administration investigational drug Patients type 1 diabetes , diabetes mellitus cause pancreas impairment , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients accept treatment arrhythmias Patients serious diabetic complication Patients habitual excessive alcohol consumption . Patients severe hepatic disorder severe renal disorder . Patients pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>